Considering lead-time bias in evaluating the effectiveness of lung cancer screening with real-world data
Open Access
- 9 June 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Scientific Reports
- Vol. 11 (1), 1-10
- https://doi.org/10.1038/s41598-021-91852-6
Abstract
Low-dose computed tomography screening can be used to diagnose lung cancer at a younger age compared to no screening. Real-world studies observing mortality after lung cancer diagnosis are subject to lead-time bias. This study developed a method using a nationwide cancer registry and stage shift from trial for the adjustment of lead-time bias. 78,897 Taiwanese nationwide lung cancer patients aged 55–82 were matched with 788,820 referents randomly selected from the general population at a ratio of 1:10 by age, sex, calendar year, and comorbidities, to estimate the pathology- and stage-specific life expectancy (LE). Loss-of-LE is the difference between the LE of cancer patients and that of referents. By multiplying LE and loss-of-LE by the pathology and stage shift in the National Lung Screening Trial (NLST), we compared the effectiveness of cancer screening measured by LE gained and loss-of-LE saved. The mean LEs of stage IA and IV adenocarcinoma were 14.5 and 1.9 years, respectively, indicating a LE gain of 12.6 years. However, the mean loss-of-LEs of stage IA and IV adenocarcinoma were 3.7 and 15.1 years, respectively, with a saving of only 11.4 years, implying an adjustment of different distributions of age, sex, and calendar year of diagnosis from stage shift and a reduction in lead-time bias. Applying such estimations on the results of 10,000 participants with the same pathology and stage shift in the NLST, the benefit of screening using LE gained would be 410.3 (95% prediction interval: 328.4 to 503.3) years. It became 297.1 (95% prediction interval: 187.8 to 396.4) years when using loss-of-LE saved, indicating the former approach would overestimate the effectiveness by 38%. Our approach of multiplying loss-of-LE by pathology and stage shift to estimate loss-of-LE saved could adjust for different distributions of age, sex, and calendar year at early diagnosis and reduce lead-time bias.Funding Information
- Ministry of Science and Technology, Taiwan (MOST108-2918-I-006-006, MOST109-2621-M-006-007)
- National Cheng Kung University Hospital, Taiwan (NCKUH-11002029)
This publication has 32 references indexed in Scilit:
- Cost-Effectiveness of Baseline Low-Dose Computed Tomography Screening for Lung Cancer: The Israeli ExperienceValue in Health, 2013
- A Cost-Utility Analysis of Lung Cancer Screening and the Additional Benefits of Incorporating Smoking Cessation InterventionsPLOS ONE, 2013
- The benefits and harms of breast cancer screening: an independent reviewBritish Journal of Cancer, 2013
- Do Physicians Understand Cancer Screening Statistics? A National Survey of Primary Care Physicians in the United StatesAnnals of Internal Medicine, 2012
- Doubling Times and CT Screen–Detected Lung Cancers in the Pittsburgh Lung Screening StudyAmerican Journal of Respiratory and Critical Care Medicine, 2012
- Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic ScreeningThe New England Journal of Medicine, 2011
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung AdenocarcinomaJournal of Thoracic Oncology, 2011
- A critical appraisal of overdiagnosis: estimates of its magnitude and implications for lung cancer screeningThorax, 2008
- Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian settingLung Cancer, 2005
- The Cost-Effectiveness of Low-Dose CT Screening for Lung Cancer*Social psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2003